<DOC>
<DOCNO>EP-0633772</DOCNO> 
<TEXT>
<INVENTION-TITLE>
MEDICAMENT AGAINST CARDIAC CIRCULATORY DISEASES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3100	A61K4508	A61K3100	A61K31519	A61K4500	A61K3152	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K45	A61K31	A61K31	A61K45	A61K31	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
MAX PLANCK GESELLSCHAFT
</APPLICANT-NAME>
<APPLICANT-NAME>
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
PODZUWEIT THOMAS
</INVENTOR-NAME>
<INVENTOR-NAME>
PODZUWEIT, THOMAS
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of erythro-9-(2-hydroxy-3-nonyl)-adenine as inhibitor
of the cGMP stimulated phosphodiesterase (PDE II) for

producing a medicine for the combating and prophylaxis of
disturbances of the cardiac rhythm, cardiac insufficiency,

angina pectoris and hypertension.
Use according to claim 1, 
characterised in that
 use takes
place together with one or more activators of guanylic

cyclase, wherein use may be simultaneous, separate or
temporally graduated.
Use according to at least one of claims 1 or 2,

characterised in that
 suitable medicines are produced for
oral, intraperitoneal, intramuscular, subcutaneous,

intraarticular or intravenous administration.
Use according to at least one of claims 1 to 3,

characterised in that
 tablets, pills, capsules, solutions or
preparations suitable for injection or infusion are produced.
Use of 2-o-propoxyphenyl-8-azapurine-6-on as inhibitor of
the cGMP stimulated phosphodiesterase (PDE II) for producing a

medicine for the combating and prophylaxis of arrhythmias and
ventricular fibrillations.
Use according to claim 5, 
characterised in that
 use takes
place together with one or more activators of the guanylic

cyclase, wherein use may be simultaneous, separate or
temporally graduated.
Use according to at least one of claims 5 or 6,

characterised in that
 suitable medicines are produced for 
oral, intraperitoneal, intramuscular, subcutaneous,

intraarticular dr intravenous administration.
Use according to at least one of claims 5 to 7,

characterised in that
 tablets, pills, capsules, solutions or
preparations for injection or infusion are produced.
</CLAIMS>
</TEXT>
</DOC>
